Efficacy of a standardized cranberry supplement on overactive bladder symptoms and urobiome alterations in young women: a randomized, double-blind, placebo-controlled pilot trial.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Urobiome dysbiosis has been implicated in the pathogenesis of overactive bladder (OAB).

Who Took Part

The abstract describes 26 women taking part.

By PubMed's age tags, the people studied were young adults and adults, women only.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and pilot.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

Neither the women nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

What Was Measured

PubMed files the paper under topics including Dietary Supplements, Dysbiosis, Lactobacillus, Microbiota, Pilot Projects, Plant Extracts and Proanthocyanidins.

The authors tagged it with the keywords cranberry, overactive bladder, randomized controlled trial and urobiome.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 26 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Frontiers in cellular and infection microbiology), a journal based in Switzerland.

More context: the Copper (Supplement) compound page, all human trials.